Alpha-blocker Plus Diuretic Combination Therapy as Second-line Treatment for Nocturia in Men

Seoul National University Hospital72 enrolled

Overview

The aim of the present study was to determine whether the combined administration of a diuretic agent, hydrochlorothiazide, at night would improve the frequency of nocturia unresponsive to alpha-blocker monotherapy in men with LUTS.

Because nocturia may result in sleep disturbances, daytime fatigue, a lower level of general well-being, and an increased risk of falling at night, it is among the most bothersome of the lower urinary tract symptoms (LUTS). Nocturia is related to a variety of conditions such as aging, overactive bladder (OAB), benign prostatic hyperplasia (BPH)/LUTS, medications, diabetes mellitus, diabetes insipidus, anorexia nervosa, and sleep disturbance. In a previous study, we suggested that treatment with terazosin can reduce episodes of nocturia, both subjectively and objectively, in some men with LUTS. Other study showed that in men with nocturnal polyuria, furosemide resulted in a significant reduction in night-time frequency and percentage of the voided volume.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nocturia

Interventions

combination therapy of terazosin and hydrochlorothiazideDRUG

25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks

Eligibility

Sex: MALE

Medical Language ↔ Plain English

Inclusion Criteria: * no response or \< 25% reduction in subjective nocturia by the IPSS question 7 after 4-weeks of treatment with terazosin * no response or \< 25% reduction in objective nocturia by the FVC after 4-weeks of treatment with terazosin * nocturia on average two times or more per night (according to the FVC) after 4-weeks of terazosin therapy Exclusion Criteria: * use of medications for the control of bladder symptoms * use of sedatives or tranquillisers for treating sleep disturbances * bladder tumours * bladder stones * urethral strictures * neurogenic bladder dysfunction * restricted mobility * working primarily at night * a documented history or clinical symptoms of prostatitis, prostate cancer, or prostatic intraepithelial neoplasia on biopsy * serum PSA levels of \>20 ng/mL * a history of prostate surgery or radiotherapy, acute urinary retention or an indwelling catheter * evidence of acute urinary infection (pyuria and bacteriuria)on urine analysis

Locations (1)

Department of Urology, Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

3-day frequency-volume chart

Time frame: at baseline and at the end of the 4-week therapy

Secondary Outcomes

International Prostate Symptom Score (IPSS) question 7

Time frame: at baseline and at the end of the 4-week therapy

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.